A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00516854

Enrollment

100

Registered

2007-08-16

Start date

2002-06-30

Completion date

2008-12-31

Last updated

2010-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chest Pain

Keywords

Non-cardiac chest pain

Brief summary

Non-cardiac chest pain is a common clinical problem encountered in our practice but at present, the results of treatments are unsatisfactory. The pathogenesis remains unknown but altered motility of the esophagus and psychological factors including anxiety have been implicated as important factors. Reports of the single use of anticholinergic drugs and anxiolytics have yielded conflicting results, has been demonstrated to yield marginal or of no value. However the use of the combination therapy, especially with a double blind fashion have not been reported. On that basis, we propose to use a combination of anti-cholinergic and tranquilliser for the symptomatic treatment of non-cardiac chest pain. The aim of this study is to evaluate the efficacy of combination therapy of anti-cholinergic and anxiolytic drugs in the treatment of non-cardiac chest pain.

Interventions

DRUGchlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Ambulatory patients over the age of 18 * Patients who are normal endoscopically * Patients who do not have symptomatic reflux disease * Patient who have normal coronary angiogram or patient with normal exercise radionuclide scan or patient with normal persantin radionuclide scan.

Exclusion criteria

* Patients with history of significant cardiac, renal, pulmonary or hepatic diseases, * Patients with history of dyspepsia or peptic ulcer diseases * Patient with documented reflux diseases. * Patient on drugs that affect gastrointestinal motility in the past 2 weeks * Patients who are pregnant or lactating * Patients who are suffering from costochrondritis * Patients who are known to be sensitive to benzodiazepine or anti-cholinergic * Patients with glaucoma and benign prostatic hypertrophy

Design outcomes

Primary

Measure	Time frame
Symptoms scores, quality of life	12 Weeks

Secondary

Measure	Time frame
Compliance	12 Weeks
Adverse effects	12 Weeks

Countries

China

Contacts

Primary ContactTing Kin Cheung, Dr

cheungtk@hkucc.hku.hk(852) 2855 3989

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026